Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Biota Jurnal Ilmu Kefarmasian Indonesia
Utama, Hieronimus Adiyoga Nareswara
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Education Environmental Science Health Professions Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Karakteristik Sel Punca Mesenkim yang Berasal dari Tali Pusat (Umbilical Cord Derived Mesenchymal Stem Cell/UCMSC) dari Macaca fascicularis dan Sekretomnya dalam Kondisi Hipoksia Dumingan, Alvian; Malik, Amarila; Rinendyaputri, Ratih; Utama, Hieronimus Adiyoga Nareswara; Sunarno, Sunarno; Purwaningtyas, Yoggi Ramadhani; Idrus, Hasta Handayani; Noverina, Rachmawati; Huda, Fathul; Faried, Ahmad
Biota Vol 17 No 1 (2024)
Publisher : Universitas Islam Negeri Mataram

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20414/jb.v17i1.492

Abstract

Mesenchymal Stem Cell (MSC) secretome has potential as a neuroprotective and neuroregenerative agent. It can have effects due to its paracrine factors, such as Brain Derived Neurotrophic Factor (BDNF) and Stromal-Cell Derived Factor-1 (SDF-1) which can be induced with hypoxia preconditioning. This compound may play a role in the treatment of neurological diseases. Stroke has become a neurological disease that contributes to high rates of mortality and morbidity worldwide. There have been several pre-clinical trials on animal stroke models using MSC secretomes from rats and humans, but no studies have been conducted on Non-Human Primate, such as Macaca fascicularis. This species has been widely used in biomedical research and part of it can be utilized for such studies which will reduce the cost of using human MSC. The results of this study, Umbilical Cord (UC)-MSCs of Macaca fascicularis have been successfully cultured and characterized in terms of phenotypic and differentiation. Hypoxia precondition was able to induce BDNF secretion up to 264 pg/mL and SDF-1 up to 666 pg/mL in the UCMSC secretome. Hypoxic preconditioning with 3% oxygen can induce the most optimal BDNF and SDF-1 secretion, compared to 1% and 5% hypoxia.
Biotechnology-based therapy for stroke treatment: review Utama, Hieronimus Adiyoga Nareswara; Mariya, Sela Septima; Dumingan, Alvian; Putri, Ratih Rinendya; Sunarno, Sunarno; Malik, Amarila
JURNAL ILMU KEFARMASIAN INDONESIA Vol 22 No 2 (2024): JIFI
Publisher : Faculty of Pharmacy, Universitas Pancasila

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35814/jifi.v22i2.1613

Abstract

Various therapeutic agents have been used to treat stroke. However, currently there is extensive exploration of new potential therapies for stroke involving novel signaling pathways and development of therapeutic agents through biotechnological approaches. This article examines the recent advances in stroke therapy using biotechnology-based drugs. We conducted a comprehensive search using specific keywords relating to Ischemic Stroke, ATMP, Peptide, Antibody, Stem Cells, and connected topics in the databases of Medline, Scopus, Web of Science, and Pubmed. The main focus of the selection criteria was on English-language literature that explored the relationship between Ischemic Stroke, ATMP, Peptide, Antibody, Stem Cells, and related factors. This article exhibits that numerous studies are being conducted and have demonstrated the use of biotechnology-based therapeutic agents for stroke, including tissue plasminogen activators, therapeutic peptides, microRNA, monoclonal antibodies, as well as stem cells. These therapeutic agents have not only been tested on test animals but have also been commenced to be tested in clinical studies or have obtained marketing approval for use in ischemic stroke patients. In conclusion, despite the limited number of approved drugs, advancements in biotechnology are poised to make them common adjunct treatments for stroke patients, not just for managing the disease but also for its cure and regenerative effects in survivors.
Co-Authors Ahmad Faried Amarila Malik Dumingan, Alvian Huda, Fathul Noverina, Rachmawati Purwaningtyas, Yoggi Ramadhani Putri, Ratih Rinendya Ratih Rinendyaputri SELA SEPTIMA MARIYA Sunarno Sunarno